Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile

被引:21
作者
Park, K
Verotta, D
Gupta, SK
Sheiner, LB [1 ]
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA
[4] ALZA Corp, Dept Clin Pharmacol, Palo Alto, CA 94303 USA
[5] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1998年 / 26卷 / 04期
关键词
pharmacodynamic model; placebo effect; drug effect; tolerance; random effect; optimal input profile; nonparametric distribution;
D O I
10.1023/A:1021068202606
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A model for the pharmacodynamic effect of a drug (designated only X), and the use of the model to explore optimal input is described. The data analyzed here are from a crossover comparison study of the effect of 4 active treatments, yielding distinct concentration vs, time curves, plus placebo in 32 subjects. The model expresses total effect as the sum of placebo effect and (pure) drug effect. The latter allows for possible tolerance (found) and time effects (not found). Random effects allow interindividual differences to be expressed. Conditioning on the fitted model, a population optimal input profile is designed that obeys certain protocol constraints The profile minimizes the expectation of a sum of squared differences between target effect and the resulting response over a given time interval. The target is a fixed constant, chosen to be either the individuals' maximum effect level in response to a baseline input regimen used in the study or the maximum effect level for the typical individual in the population in response to this regimen, as predicted from the model. The expectation ir taken over the estimated nonparametric distribution of the 32 subjects' random effects. As one goal of early clinical studies of drugs may be to provide a basis for designing an optimal delivery profile (with respect to a specified loss function), we suggest this report as an example of a reasonable way to go about finding such a profile.
引用
收藏
页码:471 / 492
页数:22
相关论文
共 23 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]  
Amrani A, 1984, IFAC 9 TRIENN WORLD, P3079
[3]  
BEAL SL, 1996, NONMEM USERS GUIDES
[4]  
COX DR, 1974, THEORETICAL STATISTI, pCH9
[5]  
D'Argenio D.Z., 1988, BIOMED MEAS INFOR CO, V2, P115
[6]   TARGETING THE SYSTEMIC EXPOSURE OF TENIPOSIDE IN THE POPULATION AND THE INDIVIDUAL USING A STOCHASTIC THERAPEUTIC OBJECTIVE [J].
DARGENIO, DZ ;
RODMAN, JH .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (02) :223-251
[7]   A nonparametric subject-specific population method for deconvolution .1. Description, internal validation, and real data examples [J].
Fattinger, KE ;
Verotta, D .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (06) :581-610
[8]   A nonparametric subject-specific population method for deconvolution .2. External validation [J].
Fattinger, KE ;
Verotta, D .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (06) :611-634
[9]   PRIORI LITHIUM DOSAGE REGIMEN USING POPULATION CHARACTERISTICS OF PHARMACOKINETIC PARAMETERS [J].
GAILLOT, J ;
STEIMER, JLJ ;
MALLET, AJ ;
THEBAULT, JJ ;
BIEDER, A .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1979, 7 (06) :579-628
[10]   A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex [J].
Gries, JM ;
Troconiz, IF ;
Verotta, D ;
Jacobson, M ;
Sheiner, LB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (01) :70-82